Search

Your search keyword '"Harbeck, N."' showing total 38 results

Search Constraints

Start Over You searched for: Author "Harbeck, N." Remove constraint Author: "Harbeck, N." Topic oncology Remove constraint Topic: oncology
38 results on '"Harbeck, N."'

Search Results

1. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

2. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

3. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

4. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

5. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

6. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

7. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)

8. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

9. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years

10. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

11. Corrigendum to '3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)' [Breast 31 (February 2017) 244-259]

12. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

14. uPA und PAI-1 haben nicht nur eine prognostische, sondern auch eine prädiktive Bedeutung und unterstützen klinische Therapieentscheidungen beim primären Mammakarzinom

15. Adjuvante Chemotherapie beim primären Mammakarzinom

16. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials

17. Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients

19. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial

20. Gene signatures in patients with early breast cancer and relapse despite pathologic complete response

21. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry

22. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

23. Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer

24. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

25. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

26. COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

27. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

28. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

29. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

30. Clinical portrait of the SARS-CoV-2 epidemic in european patients with cancer

31. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

33. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

34. Oncological care organisation during COVID-19 outbreak

35. Epigenome-based cancer risk prediction: rationale, opportunities and challenges

36. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

37. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy

38. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients

Catalog

Books, media, physical & digital resources